RU2141844C1 - Фармацевтическое соединение - Google Patents

Фармацевтическое соединение Download PDF

Info

Publication number
RU2141844C1
RU2141844C1 RU94028653A RU94028653A RU2141844C1 RU 2141844 C1 RU2141844 C1 RU 2141844C1 RU 94028653 A RU94028653 A RU 94028653A RU 94028653 A RU94028653 A RU 94028653A RU 2141844 C1 RU2141844 C1 RU 2141844C1
Authority
RU
Russia
Prior art keywords
inhibitor
glucosidase
lipase
amylase
acarbose
Prior art date
Application number
RU94028653A
Other languages
English (en)
Russian (ru)
Other versions
RU94028653A (ru
Inventor
Бремер Клаус-Дитер
Савлевич Павел
Original Assignee
Ф.Хоффманн - Ля Рош АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн - Ля Рош АГ filed Critical Ф.Хоффманн - Ля Рош АГ
Publication of RU94028653A publication Critical patent/RU94028653A/ru
Application granted granted Critical
Publication of RU2141844C1 publication Critical patent/RU2141844C1/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
RU94028653A 1993-08-05 1994-08-05 Фармацевтическое соединение RU2141844C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH2339/93 1993-08-05
CH233993 1993-08-05

Publications (2)

Publication Number Publication Date
RU94028653A RU94028653A (ru) 1996-09-10
RU2141844C1 true RU2141844C1 (ru) 1999-11-27

Family

ID=4231504

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94028653A RU2141844C1 (ru) 1993-08-05 1994-08-05 Фармацевтическое соединение

Country Status (24)

Country Link
US (1) US5643874A (https=)
EP (1) EP0638317B1 (https=)
JP (1) JP2780932B2 (https=)
KR (1) KR100342285B1 (https=)
CN (1) CN1076196C (https=)
AT (1) ATE190503T1 (https=)
AU (1) AU684793B2 (https=)
BR (1) BR9403170A (https=)
CA (1) CA2128044C (https=)
CZ (1) CZ286202B6 (https=)
DE (1) DE59409200D1 (https=)
DK (1) DK0638317T3 (https=)
ES (1) ES2144019T3 (https=)
GR (1) GR3033643T3 (https=)
HU (1) HU222346B1 (https=)
IL (1) IL110510A (https=)
NO (1) NO313490B1 (https=)
NZ (1) NZ264142A (https=)
PL (1) PL175997B1 (https=)
PT (1) PT638317E (https=)
RU (1) RU2141844C1 (https=)
SA (1) SA94150156B1 (https=)
TW (1) TW381025B (https=)
ZA (1) ZA945673B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2241462C2 (ru) * 2000-07-28 2004-12-10 Ф. Хоффманн-Ля Рош Аг Новая фармацевтическая композиция
RU2386365C2 (ru) * 2004-03-15 2010-04-20 Биоферм Ой Применение производного сорбитана для предотвращения всасывания жиров

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
PT1017408E (pt) * 1997-02-05 2005-07-29 Hoffmann La Roche Utilizacao de tetra-hidrolipstatina no tratamento de diabetes de tipo ii
HU9701081D0 (en) * 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
DE19802700A1 (de) * 1998-01-24 1999-07-29 Bayer Ag Verfahren zur Herstellung einer im Mund schnell zerfallenden Arzneiform, die als Wirkstoff Acarbose enthält
TR200100471T2 (tr) * 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri içeren farmasötik bileşimler
WO2000013667A1 (en) * 1998-09-08 2000-03-16 Smithkline Beecham Corporation Lipstatin derivative-soluble fiber tablets
DE60012301D1 (de) 1999-01-22 2004-08-26 Hunza Di Pistolesi Elvira & C Lipoproteinkomplexe und zusammensetzungen, die diese enthalten
GB9914744D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
US6235305B1 (en) * 1999-10-29 2001-05-22 2Pro Chemical Essentially nonabsorbable lipase inhibitor derivatives, pharmaceutical compositions and methods of use therefor
CN1342169A (zh) * 1999-10-29 2002-03-27 约翰·贾森·金特里·穆林斯 氧杂环丁烷酮衍生物
US6342519B2 (en) * 1999-10-29 2002-01-29 2 Pro Chemical Oxetanone derivatives
US6348492B1 (en) * 1999-10-29 2002-02-19 2Pro Chemical Oxetanone derivatives
KR100349334B1 (ko) * 1999-12-08 2002-08-21 박관화 아카비오신 글루코실 시몬진 및 그것의 제조방법.
US7713546B1 (en) 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
EP1307263B1 (en) * 2000-07-28 2005-04-20 F. Hoffmann-La Roche Ag New use of lipase inhibitors
US6849609B2 (en) * 2001-04-10 2005-02-01 James U. Morrison Method and composition for controlled release acarbose formulations
EP1470116A4 (en) 2001-12-04 2005-04-06 Biogal Gyogyszergyar PREPARATION OF THE ORLISTAT AND CRYSTALLINE FORMS OF THE ORLISTAT
US7108869B2 (en) * 2002-11-07 2006-09-19 Access Business Group International Llc Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US20060185357A1 (en) * 2004-05-07 2006-08-24 Kovacevich Ian D Independently drawing and tensioning lines with bi-directional rotary device having two spools
CN1980682A (zh) 2004-05-10 2007-06-13 丹麦皇家兽医和农业学院 用于控制体重的亚麻子
US20060029567A1 (en) 2004-08-04 2006-02-09 Bki Holding Corporation Material for odor control
AP2007003979A0 (en) * 2004-11-23 2007-06-30 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
US8283312B2 (en) * 2005-02-04 2012-10-09 The Research Foundation Of State University Of New York Compositions and methods for modulating body weight and treating obesity-related disorders
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation
WO2006119038A1 (en) * 2005-04-29 2006-11-09 Naturegen, Inc. Compositions and methods for controlling glucose uptake
ES2434072T3 (es) * 2005-06-09 2013-12-13 Norgine Bv Preparación sólida de 2-hexadeciloxi-6-metil-4H-3,1-benzoxacin-4-ona
CA2617654A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
CN100349614C (zh) * 2005-10-21 2007-11-21 南京工业大学 一种含α－淀粉酶抑制剂的固体混合物及其制备工艺和在制药中的应用
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
WO2007096763A2 (en) * 2006-02-23 2007-08-30 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
AR063275A1 (es) * 2006-10-12 2009-01-14 Epix Delaware Inc Compuestos de carboxamida, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de ccr2.
CN101583593A (zh) 2006-11-13 2009-11-18 辉瑞产品公司 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途
WO2008062276A2 (en) * 2006-11-20 2008-05-29 Glenmark Pharmaceuticals S.A. Acetylene derivatives as stearoyl coa desaturase inhibitors
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
SI2002825T1 (sl) * 2007-06-14 2013-10-30 Krka Farmacevtski sestavki, ki obsegajo orlistat
EP2190303A1 (en) 2007-09-12 2010-06-02 Københavns Universitet Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
US20100317642A1 (en) * 2007-10-15 2010-12-16 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
BRPI0820701A2 (pt) 2007-12-11 2015-06-16 Cytopathfinder Inc Composto de carboxamida e seu uso como agonistas do receptor de quimiocina
KR101280786B1 (ko) * 2008-08-06 2013-07-05 화이자 리미티드 멜라노코르틴 4 작용제로서 다이아제핀 및 다이아조칸 화합물
RU2441654C2 (ru) * 2010-02-17 2012-02-10 Лабораториос Баго С.А. Фармацевтическая композиция с активностью против ожирения, включающая премикс чистого орлистата, и способ ее изготовления
JP5752359B2 (ja) * 2010-02-25 2015-07-22 富士フイルム株式会社 体重増加抑制組成物及びこれを含む食品
US20130072519A1 (en) 2010-05-21 2013-03-21 Edward Lee Conn 2-phenyl benzoylamides
TR201100148A2 (tr) * 2011-01-06 2012-07-23 Bi̇lgi̇ç Mahmut Stabil akarboz förmülasyonları.
EP2680874A2 (en) 2011-03-04 2014-01-08 Pfizer Inc Edn3-like peptides and uses thereof
CN102805744A (zh) * 2011-06-02 2012-12-05 鲁南制药集团股份有限公司 一种治疗或预防肥胖症以及代谢综合症的药物组合物
CN102872062A (zh) * 2011-07-13 2013-01-16 鲁南制药集团股份有限公司 一种治疗或预防肥胖症以及代谢综合症的药物组合物
US8252312B1 (en) * 2011-12-27 2012-08-28 David Wong Oral solid composition comprising a lipid absorption inhibitor
US20150050371A1 (en) 2012-03-09 2015-02-19 Biotropics Malaysia Berhad Extract Formulations of Rhodamnia Cinerea And Uses Thereof
JP2016510306A (ja) * 2012-05-08 2016-04-07 セリックスビオ プライヴェート リミテッド 高血糖の治療のための組成物及び方法
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
FR3017536B1 (fr) 2014-02-18 2017-05-26 Univ La Rochelle Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
KR101937069B1 (ko) * 2014-12-17 2019-04-03 엠프로스 파마 악티에볼라그 비만 및 관련 대사 장애의 치료를 위한 오를리스타트 및 아카르보스의 변형 방출형 조성물
KR101903150B1 (ko) 2016-09-12 2018-10-01 가톨릭대학교산학협력단 퀴니자린을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물
CN107308154A (zh) * 2017-07-19 2017-11-03 重庆植恩药业有限公司 治疗或预防肥胖症以及代谢综合征的药物组合物及其应用
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
US20240226024A1 (en) * 2021-05-21 2024-07-11 Empros Pharma Ab Synergistic effects on weight loss, improved quality of life and reduced gastro-intestinal side effects with a composition of orlistat and acarbose
US20250127752A1 (en) * 2021-05-21 2025-04-24 Empros Pharma Ab Reduced rebound effects in subjects treated for overweight or obesity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451465A (en) * 1981-07-07 1984-05-29 John Wyeth & Brother Ltd. Anti-obesity agents
US4632925A (en) * 1985-10-07 1986-12-30 Hoffmann-La Roche Inc. N-substituted diphenylpiperidines and antiobesity use thereof
SU1697823A1 (ru) * 1988-08-01 1991-12-15 Киевский государственный институт усовершенствования врачей Способ лечени алиментарно-конституционального ожирени

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
JPS5953920B2 (ja) * 1977-12-28 1984-12-27 東洋醸造株式会社 新規なアミノ糖化合物およびその製法
CA1121290A (en) * 1978-02-14 1982-04-06 Yasuji Suhara Amino sugar derivatives
JPS56128774A (en) * 1980-03-14 1981-10-08 Microbial Chem Res Found New physiologically active substance ebelactone and its preparation
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
FI844289L (fi) * 1984-01-21 1985-07-22 Hoechst Ag Nya polypeptider med -amylashaemmande verkan, foerfarande foer deras framstaellning, deras anvaendning och farmaceutiska preparat.
US4952567A (en) * 1988-05-09 1990-08-28 City Of Hope Inhibition of lipogenesis
EP0364696B1 (en) * 1988-08-22 1993-03-17 Takeda Chemical Industries, Ltd. Alpha-glucosidase inhibitor as a calcium absorption promotor
DK244090D0 (da) * 1990-10-09 1990-10-09 Novo Nordisk As Kemiske forbindelser
US5240962A (en) * 1991-04-15 1993-08-31 Takasago Institute For Interdisciplinary Science, Inc. Antiobesity and fat-reducing agents
GB9122051D0 (en) * 1991-10-17 1991-11-27 Univ Nottingham Medicines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451465A (en) * 1981-07-07 1984-05-29 John Wyeth & Brother Ltd. Anti-obesity agents
US4632925A (en) * 1985-10-07 1986-12-30 Hoffmann-La Roche Inc. N-substituted diphenylpiperidines and antiobesity use thereof
SU1697823A1 (ru) * 1988-08-01 1991-12-15 Киевский государственный институт усовершенствования врачей Способ лечени алиментарно-конституционального ожирени

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2241462C2 (ru) * 2000-07-28 2004-12-10 Ф. Хоффманн-Ля Рош Аг Новая фармацевтическая композиция
RU2386365C2 (ru) * 2004-03-15 2010-04-20 Биоферм Ой Применение производного сорбитана для предотвращения всасывания жиров

Also Published As

Publication number Publication date
RU94028653A (ru) 1996-09-10
KR100342285B1 (ko) 2002-10-25
US5643874A (en) 1997-07-01
PL175997B1 (pl) 1999-03-31
GR3033643T3 (en) 2000-10-31
TW381025B (en) 2000-02-01
AU6883994A (en) 1995-02-16
NO942900L (no) 1995-02-06
ES2144019T3 (es) 2000-06-01
CZ286202B6 (cs) 2000-02-16
NO313490B1 (no) 2002-10-14
PT638317E (pt) 2000-07-31
CZ182594A3 (en) 1995-02-15
EP0638317B1 (de) 2000-03-15
IL110510A0 (en) 1994-11-11
ATE190503T1 (de) 2000-04-15
ZA945673B (en) 1995-02-07
BR9403170A (pt) 1995-04-18
CN1106701A (zh) 1995-08-16
HUT68300A (en) 1995-06-28
JPH0753409A (ja) 1995-02-28
PL304557A1 (en) 1995-02-06
HU9402249D0 (en) 1994-09-28
DK0638317T3 (da) 2000-06-26
EP0638317A1 (de) 1995-02-15
JP2780932B2 (ja) 1998-07-30
IL110510A (en) 1999-03-12
CA2128044A1 (en) 1995-02-06
DE59409200D1 (de) 2000-04-20
HU222346B1 (hu) 2003-06-28
KR950005319A (ko) 1995-03-20
SA94150156B1 (ar) 2005-05-15
NZ264142A (en) 1996-11-26
CA2128044C (en) 2007-02-20
CN1076196C (zh) 2001-12-19
AU684793B2 (en) 1998-01-08
NO942900D0 (https=) 1994-08-04

Similar Documents

Publication Publication Date Title
RU2141844C1 (ru) Фармацевтическое соединение
US5665352A (en) Process for reducing the extent of cryptosporidium diarrhoeas
US8318218B2 (en) Composition comprising 1,3/1, 6 beta glucan for reducing weight
JPH10502644A (ja) 免疫機能の調整方法
US5846944A (en) Purified SDG as an antioxidant
Barrowman et al. Diarrhoeae in thyroid medullary carcinoma: role of prostaglandins and therapeutic effect of nutmeg.
US5364636A (en) Inhibitor of absorption of digestion product of food and drink
Hayakawa et al. Pneumatosis cystoides intestinalis after treatment with an alpha-glucosidase inhibitor
Guerra et al. Further trials of nifurtimox in mucocutaneous leishmaniasis
NL8105635A (nl) Geneesmiddel met transplantaatafstotings- en/of immunologische ontstekingsremmende werking, alsmede werkwijze voor de remming van transplantaatafstoting en/of immunologische ontsteking.
NO974486L (no) Lavdoserte "Ridogrel"-formuleringer samt anvendelse derav ved behandling av tarmbetennelse
US20020016307A1 (en) Pharmaceutical composition with both a lipase inhibitor and a lipophilic polysaccharide and an improved method for treating adiposity
RU2149013C1 (ru) Биостимулирующее средство и способ лечения соматических заболеваний
RU2178304C1 (ru) Способ комплексного лечения хронического панкреатита
RU2175235C1 (ru) Способ вспомогательных терапии и профилактики желудочно-кишечных болезней молодняка кур
SU1122318A1 (ru) Способ лечени синдрома раздраженного кишечника
US3904758A (en) Method of increasing wakefulness
SU1252333A1 (ru) Способ лечени дисбактериозов кишечника
RU2161497C2 (ru) Способ лечения дисбактериозов кишечника у детей и взрослых
Rapes Studies of a Newly Described Gastrointestinal Factor and Its Role in Protecting Against the Negative Effects of Food
RU2112509C1 (ru) Способ лечения инсулиннезависимого сахарного диабета (ii тип), сопровождающегося ожирением
WO2002026104A2 (en) A combination of appetite controlling agents which create a synergy and produce a satiating result
de Haen New Drug Introduction 1973-1974
WO1999037311A1 (en) Cellulose derivatives and colorectal cancer risk reduction
PHILLIPS et al. Testosterone FSH Slh